ATAI

AtaiBeckley Inc.

Price Chart

Latest Quote

$4.14

+0.30 (+7.81%)

Current Price

Previous Close	$3.84
Open	$3.84
Day High	$4.34
Day Low	$3.83
Volume	9,958,442

Fetched: 2026-06-17T11:14:43

Stock Information

Shares Outstanding	368.17M
Total Debt	$5.14M
Cash Equivalents	$230.77M
Revenue	$3.49M
Net Income	$-663.40M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.52B
EPS (TTM)	$-2.84
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$1.30B
Sales	$3.49M
Income	$-663.40M
Book/sh	$0.56
Cash/sh	$0.63
Employees	99

Financial Ratios

Quick Ratio	9.81
Current Ratio	10.02
Debt/Eq	2.58

Returns & Margins

ROA	-33.34%
ROE	-378.00%
Operating Margin	-3239.10%

Ownership

Insider Ownership	2.35%
Institutional Ownership	43.51%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-9.10
P/S	436.99
P/B	7.45

Analyst Data

Recommendation	strong_buy
Target Price	$14.00

Technical Indicators

SMA20	$nan
SMA50	$nan
SMA200	$nan
RSI	37.50
ATR	nan

Shares Float	303.91M
Short Float	6.99%
Short Ratio	4.96
Volatility	1.60
Rel Volume	1.88

Performance History

Week	nan%
Month	nan%
Quarter	nan%
6 Months	nan%
YTD	nan%
Year	nan%
3 Years	nan%
10 Years	nan%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-16	$nan	9,965,519
2026-06-15	$3.84	3,351,500
2026-06-12	$3.92	4,980,900
2026-06-11	$3.80	4,858,500
2026-06-10	$3.78	3,280,900
2026-06-09	$3.89	5,405,400
2026-06-08	$3.81	4,929,000
2026-06-05	$3.95	9,241,000
2026-06-04	$4.50	4,553,800
2026-06-03	$4.53	4,836,400
2026-06-02	$4.81	7,196,500
2026-06-01	$4.82	7,033,200
2026-05-29	$4.53	6,028,600
2026-05-28	$4.41	4,303,700
2026-05-27	$4.32	4,542,000
2026-05-26	$4.29	4,589,500
2026-05-22	$4.32	5,015,800
2026-05-21	$4.33	4,028,900
2026-05-20	$4.09	3,458,900
2026-05-19	$3.96	4,560,500
2026-05-18	$4.15	7,869,600

About AtaiBeckley Inc.

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.

📰 Latest News

Wall Street Bullish on AtaiBeckley (ATAI), Here’s Why

Insider Monkey • 2026-06-16T18:45:39Z

Is AtaiBeckley Inc. (ATAI) the Hidden Penny Stock to Invest In?

Insider Monkey • 2026-06-13T15:30:55Z

Atai Beckley N.V. (ATAI) A Top Penny Stock to Buy Poised to Build Sustained Clinical and Shareholder Value

Insider Monkey • 2026-06-07T17:57:22Z

AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat ‘Buy’ rating

Proactive • 2026-06-04T17:38:00Z

Is AtaiBeckley’s BPL-003 Phase 3 Launch Altering The Investment Case For AtaiBeckley (ATAI)?

Simply Wall St. • 2026-06-04T06:11:48Z

Assessing AtaiBeckley (ATAI) Valuation After Strong Returns And Elevated Price To Book Ratio

Simply Wall St. • 2026-06-04T02:12:22Z

AtaiBeckley launches mental health patient impact grant program

Proactive • 2026-05-28T13:57:00Z

AtaiBeckley (ATAI) Reports Q1 Financial Results

Insider Monkey • 2026-05-22T18:43:49Z

A Look At AtaiBeckley (ATAI) Valuation As Share Price Momentum And DCF Signal Differ

Simply Wall St. • 2026-05-16T00:22:04Z

AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says

Proactive • 2026-05-13T17:06:00Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$4,089,000	$308,000	$314,000	$233,000
Operating Revenue	$4,089,000	$308,000	$314,000	$233,000
Expenses
Interest Expense	$1,162,000	$3,124,000	$2,656,000	$923,000
Total Expenses	$117,436,000	$102,474,000	$123,340,000	$144,663,000
Other Income Expense	$-546,818,000	$-43,893,000	$84,549,000	$9,623,000
Other Non Operating Income Expenses	$-2,589,000	$5,898,000	$-189,000	$-489,000
Net Non Operating Interest Income Expense	$316,000	$-2,346,000	$-809,000	$-375,000
Interest Expense Non Operating	$1,162,000	$3,124,000	$2,656,000	$923,000
Operating Expense	$117,436,000	$102,474,000	$123,340,000	$144,663,000
General And Administrative Expense	$65,088,000	$47,544,000	$63,582,000	$70,350,000
Other Operating Expenses	-	$-525,000	$-2,445,000	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-660,047,000	$-149,269,000	$-40,224,000	$-152,385,000
Net Interest Income	$316,000	$-2,346,000	$-809,000	$-375,000
Interest Income	$1,478,000	$778,000	$1,847,000	$548,000
Normalized Income	$-230,106,090	$-99,597,441	$-107,167,020	$-160,373,480
Net Income From Continuing And Discontinued Operation	$-660,047,000	$-149,269,000	$-40,224,000	$-152,385,000
Total Operating Income As Reported	$-644,061,000	$-102,691,000	$-125,471,000	$-144,787,000
Net Income Common Stockholders	$-660,047,000	$-149,269,000	$-40,224,000	$-152,385,000
Net Income	$-660,047,000	$-149,269,000	$-40,224,000	$-152,385,000
Net Income Including Noncontrolling Interests	$-660,147,000	$-150,049,000	$-43,895,000	$-157,417,000
Net Income Continuous Operations	$-660,147,000	$-150,049,000	$-43,895,000	$-157,417,000
Earnings From Equity Interest Net Of Tax	$0	$-2,000,000	$-3,593,000	$-16,006,000
Pretax Income	$-659,849,000	$-148,405,000	$-39,286,000	$-135,182,000
Special Income Charges	$-525,515,000	$1,166,000	$-951,000	$1,127,000
Interest Income Non Operating	$1,478,000	$778,000	$1,847,000	$548,000
Operating Income	$-113,347,000	$-102,166,000	$-123,026,000	$-144,430,000
Earnings From Equity Interest	-	-	-	-
Per Share
Diluted EPS	$-2.91	$-0.93	$-0.25	$-0.98
Basic EPS	$-2.91	$-0.93	$-0.25	$-0.98
Other
Tax Effect Of Unusual Items	$-114,288,090	$-119,441	$17,794,980	$2,123,520
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-113,446,000	$-95,017,000	$-121,049,000	$-144,203,000
Total Unusual Items	$-544,229,000	$-49,791,000	$84,738,000	$10,112,000
Total Unusual Items Excluding Goodwill	$-544,229,000	$-49,791,000	$84,738,000	$10,112,000
Reconciled Depreciation	$1,012,000	$473,000	$319,000	$168,000
EBITDA (Bullshit earnings)	$-657,675,000	$-144,808,000	$-36,311,000	$-134,091,000
EBIT	$-658,687,000	$-145,281,000	$-36,630,000	$-134,259,000
Diluted Average Shares	$226,532,786	$160,159,983	$158,833,785	$155,719,585
Basic Average Shares	$226,532,786	$160,159,983	$158,833,785	$155,719,585
Diluted NI Availto Com Stockholders	$-660,047,000	$-149,269,000	$-40,224,000	$-152,385,000
Minority Interests	$100,000	$780,000	$3,671,000	$5,032,000
Tax Provision	$298,000	$-356,000	$1,016,000	$6,229,000
Gain On Sale Of Ppe	$-692,000	$0	-	-
Gain On Sale Of Business	$0	$1,166,000	$60,000	$1,484,000
Other Special Charges	$524,823,000	-	-	$357,000
Gain On Sale Of Security	$-18,714,000	$-50,957,000	$85,689,000	$8,985,000
Other Taxes	$-714,000	$-525,000	-	-
Research And Development	$53,062,000	$55,455,000	$62,203,000	$74,313,000
Selling General And Administration	$65,088,000	$47,544,000	$63,582,000	$70,350,000
Other Gand A	$65,088,000	$47,544,000	$63,582,000	$70,350,000
Write Off	-	$0	$1,011,000	$0
Restructuring And Mergern Acquisition	-	$-5,567,000	$0	$-2,959,000

Fetched: 2026-06-13

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$218,692,000	$112,720,000	$241,190,000	$260,740,000
Total Assets	$292,723,000	$159,387,000	$293,478,000	$305,441,000
Total Non Current Assets	$17,039,000	$79,262,000	$107,886,000	$18,296,000
Other Non Current Assets	$1,110,000	$850,000	$948,000	$3,125,000
Investmentin Financial Assets	$0	$42,079,000	$1,838,000	$6,755,000
Goodwill And Other Intangible Assets	$3,182,000	$3,577,000	$1,772,000	-
Other Intangible Assets	$2,851,000	$3,246,000	$1,772,000	-
Current Assets	$275,684,000	$80,125,000	$185,592,000	$287,145,000
Other Current Assets	$946,000	$421,000	$846,000	$1,745,000
Restricted Cash	$0	$10,000,000	$0	-
Prepaid Assets	$4,271,000	$5,672,000	$3,232,000	$6,660,000
Receivables	$14,427,000	$1,702,000	$2,257,000	$5,631,000
Taxes Receivable	$13,135,000	$1,348,000	$1,752,000	$5,631,000
Notes Receivable	$625,000	$0	$505,000	$0
Accounts Receivable	$667,000	$354,000	-	-
Cash Cash Equivalents And Short Term Investments	$256,040,000	$62,330,000	$179,257,000	$273,109,000
Cash And Cash Equivalents	$85,300,000	$17,505,000	$45,034,000	$190,613,000
Non Current Note Receivables	-	$0	$11,299,000	$7,262,000
Non Current Deferred Assets	-	-	-	-
Debt
Total Debt	$2,072,000	$24,706,000	$19,142,000	$15,341,000
Long Term Debt And Capital Lease Obligation	$1,801,000	$14,865,000	$18,867,000	$15,161,000
Current Debt And Capital Lease Obligation	$271,000	$9,841,000	$275,000	$180,000
Net Debt	-	$5,992,000	-	-
Long Term Debt	-	$14,133,000	$17,877,000	$15,117,000
Current Debt	-	$9,364,000	-	-
Other Current Borrowings	-	$9,364,000	-	-
Liabilities
Total Liabilities Net Minority Interest	$70,722,000	$42,833,000	$49,162,000	$39,675,000
Total Non Current Liabilities Net Minority Interest	$47,243,000	$17,882,000	$29,042,000	$19,778,000
Other Non Current Liabilities	$1,063,000	$3,017,000	$10,175,000	$4,617,000
Derivative Product Liabilities	$44,379,000	$0	-	-
Current Liabilities	$23,479,000	$24,951,000	$20,120,000	$19,897,000
Other Current Liabilities	$3,144,000	$2,463,000	$1,101,000	$718,000
Current Deferred Liabilities	$1,524,000	$721,000	-	-
Payables And Accrued Expenses	$18,540,000	$11,926,000	$18,744,000	$18,999,000
Payables	$4,926,000	$2,804,000	$5,304,000	$4,623,000
Total Tax Payable	$20,000	$188,000	$715,000	$2,224,000
Accounts Payable	$4,906,000	$2,616,000	$4,589,000	$2,399,000
Equity
Common Stock Equity	$221,874,000	$116,297,000	$242,962,000	$260,740,000
Total Equity Gross Minority Interest	$222,001,000	$116,554,000	$244,316,000	$265,766,000
Stockholders Equity	$221,874,000	$116,297,000	$242,962,000	$260,740,000
Gains Losses Not Affecting Retained Earnings	$-20,926,000	$-18,466,000	$-19,460,000	$-21,702,000
Other Equity Adjustments	$-20,926,000	$-18,466,000	$-19,460,000	$-21,702,000
Retained Earnings	$-1,360,254,000	$-700,207,000	$-550,938,000	$-510,188,000
Other Equity Interest	-	-	-	$-24,000
Long Term Equity Investment	-	-	-	$0
Investments In Other Ventures Under Equity Method	-	-	-	-
Other
Ordinary Shares Number	$363,280,522	$167,959,752	$166,026,396	$165,935,914
Share Issued	$363,280,522	$167,959,752	$166,026,396	$165,935,914
Tangible Book Value	$218,692,000	$112,720,000	$241,190,000	$260,740,000
Invested Capital	$221,874,000	$139,794,000	$260,839,000	$275,857,000
Working Capital	$252,205,000	$55,174,000	$165,472,000	$267,248,000
Capital Lease Obligations	$2,072,000	$1,209,000	$1,265,000	$224,000
Total Capitalization	$221,874,000	$130,430,000	$260,839,000	$275,857,000
Minority Interest	$127,000	$257,000	$1,354,000	$5,026,000
Additional Paid In Capital	$1,599,421,000	$816,185,000	$794,787,000	$774,092,000
Capital Stock	$3,633,000	$18,785,000	$18,573,000	$18,562,000
Common Stock	$3,633,000	$18,785,000	$18,573,000	$18,562,000
Preferred Stock	$0	$0	-	-
Long Term Capital Lease Obligation	$1,801,000	$732,000	$990,000	$44,000
Current Deferred Revenue	$1,524,000	$721,000	-	-
Current Capital Lease Obligation	$271,000	$477,000	$275,000	$180,000
Current Accrued Expenses	$13,614,000	$9,122,000	$13,440,000	$14,376,000
Investments And Advances	$8,735,000	$70,966,000	$91,663,000	$6,755,000
Other Investments	$8,735,000	$28,887,000	$89,825,000	$0
Goodwill	$331,000	$331,000	$0	-
Net PPE	$4,012,000	$3,869,000	$2,204,000	$1,154,000
Accumulated Depreciation	$-405,000	$-398,000	$-153,000	-
Gross PPE	$4,417,000	$4,267,000	$2,357,000	$1,154,000
Leases	$564,000	$0	-	-
Other Properties	$3,580,000	$2,906,000	$1,223,000	$1,154,000
Machinery Furniture Equipment	$273,000	$1,361,000	$1,134,000	-
Properties	$0	$0	-	-
Other Short Term Investments	$170,740,000	$44,825,000	$134,223,000	$82,496,000
Available For Sale Securities	-	$42,079,000	$1,838,000	$6,755,000
Treasury Shares Number	-	-	$0	-

Fetched: 2026-06-13

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-113,543,000	$-82,532,000	$-84,708,000	$-105,491,000
Operating Activities
Operating Cash Flow	$-102,675,000	$-82,437,000	$-84,118,000	$-104,467,000
Cash Flow From Continuing Operating Activities	$-102,675,000	$-82,437,000	$-84,118,000	$-104,467,000
Operating Gains Losses	$521,879,000	$652,000	$4,332,000	$9,572,000
Investing Activities
Capital Expenditure	$-10,868,000	$-95,000	$-590,000	$-1,024,000
Investing Cash Flow	$-109,127,000	$59,172,000	$-53,295,000	$-86,848,000
Cash Flow From Continuing Investing Activities	$-109,127,000	$59,172,000	$-53,296,000	$-86,848,000
Net Other Investing Changes	$-10,000,000	$-7,745,000	$-5,513,000	$-3,000,000
Capital Expenditure Reported	$0	$-89,000	$-331,000	$-251,000
Financing Activities
Repurchase Of Capital Stock	$-6,635,000	$0	-	-
Issuance Of Capital Stock	$258,128,000	$0	$0	$600,000
Financing Cash Flow	$269,481,000	$5,374,000	$-8,355,000	$20,785,000
Cash Flow From Continuing Financing Activities	$269,481,000	$5,374,000	$-8,355,000	$20,785,000
Net Other Financing Charges	$-13,952,000	$-161,000	$-8,560,000	$2,891,000
Net Common Stock Issuance	$251,493,000	$0	-	$0
Common Stock Issuance	$258,128,000	$0	-	$0
Net Preferred Stock Issuance	-	-	$0	$600,000
Preferred Stock Issuance	-	-	$0	$600,000
Other
Issuance Of Debt	$0	$5,000,000	$0	$15,000,000
Interest Paid Supplemental Data	$793,000	$2,159,000	$1,923,000	-
Income Tax Paid Supplemental Data	$589,000	$411,000	$1,475,000	-
End Cash Position	$85,300,000	$27,505,000	$45,034,000	$190,613,000
Beginning Cash Position	$27,505,000	$45,034,000	$190,613,000	$362,266,000
Effect Of Exchange Rate Changes	$116,000	$362,000	$189,000	$-1,123,000
Changes In Cash	$57,679,000	$-17,891,000	$-145,768,000	$-170,530,000
Proceeds From Stock Option Exercised	$31,940,000	$535,000	$205,000	$2,294,000
Common Stock Payments	$-6,635,000	$0	-	-
Net Issuance Payments Of Debt	$0	$5,000,000	$0	$15,000,000
Net Long Term Debt Issuance	$0	$5,000,000	$0	$15,000,000
Long Term Debt Issuance	$0	$5,000,000	$0	$15,000,000
Net Investment Purchase And Sale	$-92,895,000	$66,653,000	$-46,749,000	$-82,824,000
Sale Of Investment	$9,050,000	$81,653,000	$139,469,000	$226,834,000
Purchase Of Investment	$-101,945,000	$-15,000,000	$-186,218,000	$-309,658,000
Net Business Purchase And Sale	$4,636,000	$359,000	$-443,000	$0
Sale Of Business	$4,636,000	$359,000	$0	-
Net Intangibles Purchase And Sale	$-9,967,000	$0	$0	-
Purchase Of Intangibles	$-9,967,000	$0	$0	-
Net PPE Purchase And Sale	$-901,000	$-6,000	$-259,000	$-773,000
Purchase Of PPE	$-901,000	$-6,000	$-259,000	$-773,000
Change In Working Capital	$-6,475,000	$-9,200,000	$7,469,000	$-3,335,000
Change In Other Working Capital	$766,000	$721,000	-	-
Change In Payables And Accrued Expense	$-7,932,000	$-8,830,000	$-1,194,000	$-1,813,000
Change In Accrued Expense	$-6,237,000	$-6,958,000	$-3,332,000	$1,221,000
Change In Payable	$-1,695,000	$-1,872,000	$2,138,000	$-3,034,000
Change In Account Payable	$-1,695,000	$-1,872,000	$2,138,000	$-3,034,000
Change In Prepaid Assets	$691,000	$-1,091,000	$8,663,000	$-1,522,000
Other Non Cash Items	$26,810,000	$44,543,000	$-86,336,000	$-1,756,000
Stock Based Compensation	$14,213,000	$25,490,000	$32,982,000	$42,375,000
Unrealized Gain Loss On Investment Securities	$0	$2,075,000	$0	$-272,000
Asset Impairment Charge	$33,000	$3,579,000	$1,011,000	$852,000
Depreciation Amortization Depletion	$1,012,000	$473,000	$319,000	$168,000
Depreciation And Amortization	$1,012,000	$473,000	$319,000	$168,000
Earnings Losses From Equity Investments	$0	$2,000,000	$3,593,000	$16,006,000
Gain Loss On Investment Securities	$527,563,000	$-1,260,000	-	$-336,000
Net Foreign Currency Exchange Gain Loss	$-2,024,000	$1,078,000	$799,000	$-4,950,000
Gain Loss On Sale Of PPE	$692,000	$0	-	-
Gain Loss On Sale Of Business	$-6,902,000	$-1,166,000	$-60,000	$-1,484,000
Net Income From Continuing Operations	$-660,147,000	$-150,049,000	$-43,895,000	$-157,417,000
Purchase Of Business	-	$0	$-443,000	$0
Deferred Tax	-	-	$0	$5,074,000
Deferred Income Tax	-	-	$0	$5,074,000

Fetched: 2026-06-13